Who makes Neosil complete?

Neosil complete is developed by EMS.

What development phase is Neosil complete in?

Neosil complete is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Neosil complete

EMS · FDA-approved active Small molecule Quality 0/100

Neosil complete, marketed by EMS, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and revenue generation, though specific figures are not disclosed. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Neosil complete
Sponsor	EMS
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Neosil on Chronic Effluvium (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Neosil complete CI brief — competitive landscape report
Neosil complete updates RSS · CI watch RSS
EMS portfolio CI